ARROWHEAD PHARMACEUTICALS, INC. Increase (Decrease) in Receivables
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Increase (Decrease) in Receivables of $1.05 million for the 3-month period ending 2015-12-31, per its 10-Q filed 2016-02-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInReceivables · last filed 2016-02-09
- ARROWHEAD PHARMACEUTICALS, INC. increase (decrease) in receivables for the quarter ending 2015-12-31 was $1.05M, a 672.65% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. increase (decrease) in receivables for the quarter ending 2014-12-31 was $136.51K, a 1054.38% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. increase (decrease) in receivables for the quarter ending 2014-09-30 was $0.00, a 100.00% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. increase (decrease) in receivables for the quarter ending 2014-06-30 was $0.00.
- ARROWHEAD PHARMACEUTICALS, INC. increase (decrease) in receivables for fiscal 2014 was -$75.00K, a 214.29% decline from fiscal 2013.
- ARROWHEAD PHARMACEUTICALS, INC. increase (decrease) in receivables for fiscal 2013 was $65.63K.
- ARROWHEAD PHARMACEUTICALS, INC. increase (decrease) in receivables for fiscal 2012 was -$162.85K.
| Period end | Increase (Decrease) in Receivables 3 month | Increase (Decrease) in Receivables 3 month as first filed | Increase (Decrease) in Receivables 6 month | Increase (Decrease) in Receivables 9 month | Increase (Decrease) in Receivables 12 month | Increase (Decrease) in Receivables 98 month | Increase (Decrease) in Receivables 101 month | Increase (Decrease) in Receivables 104 month | Increase (Decrease) in Receivables 107 month | Increase (Decrease) in Receivables 110 month | Increase (Decrease) in Receivables 113 month | Increase (Decrease) in Receivables 116 month | Increase (Decrease) in Receivables 119 month | Increase (Decrease) in Receivables 122 month | Increase (Decrease) in Receivables 128 month | Increase (Decrease) in Receivables 131 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2015-12-31 | $1.05M 10-Q · filed 2016-02-09 | |||||||||||||||
| 2014-12-31 | $136.51K 10-Q · filed 2016-02-09 | $127.00K 10-Q · filed 2015-02-09 | $136.51K derived: sum of 2 quarters · filed 2016-02-09 | $136.51K derived: sum of 3 quarters · filed 2016-02-09 | $49.68K derived: sum of 4 quarters · filed 2016-02-09 | |||||||||||
| 2014-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-14 | $0.00 derived: sum of 2 quarters · filed 2015-12-14 | -$86.83K derived: sum of 3 quarters · filed 2015-12-14 | -$75.00K 10-K · filed 2015-12-14 | ||||||||||||
| 2014-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-08-04 | -$86.83K derived: sum of 2 quarters · filed 2015-08-04 | -$75.00K 10-Q · filed 2015-08-04 | $0.00 derived: sum of 4 quarters · filed 2015-12-14 | ||||||||||||
| 2014-03-31 | -$86.83K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-05-11 | -$75.00K 10-Q · filed 2015-05-11 | $0.00 derived: sum of 3 quarters · filed 2015-12-14 | $0.00 derived: sum of 4 quarters · filed 2015-12-14 | -$109.42K 10-Q · filed 2014-05-06 | |||||||||||
| 2013-12-31 | $11.82K 10-Q · filed 2015-02-09 | $86.83K derived: sum of 2 quarters · filed 2015-12-14 | $86.83K derived: sum of 3 quarters · filed 2015-12-14 | -$28.44K derived: sum of 4 quarters · filed 2015-12-14 | -$34.41K 10-Q · filed 2014-02-04 | |||||||||||
| 2013-09-30 | $75.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-14 | $75.00K derived: sum of 2 quarters · filed 2015-12-14 | -$40.27K derived: sum of 3 quarters · filed 2015-12-14 | $65.63K 10-K · filed 2015-12-14 | ||||||||||||
| 2013-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-08-12 | -$115.27K derived: sum of 2 quarters · filed 2014-08-12 | -$9.38K 10-Q · filed 2014-08-12 | -$3.08K derived: sum of 4 quarters · filed 2014-08-12 | -$109.42K 10-Q · filed 2013-08-07 | |||||||||||
| 2013-03-31 | -$115.27K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-05-06 | -$9.38K 10-Q · filed 2014-05-06 | -$3.08K derived: sum of 3 quarters · filed 2014-05-06 | -$22.66K derived: sum of 4 quarters · filed 2014-05-06 | -$109.42K 10-Q · filed 2013-05-09 | |||||||||||
| 2012-12-31 | $105.89K 10-Q · filed 2014-02-04 | $112.19K derived: sum of 2 quarters · filed 2014-02-04 | $92.61K derived: sum of 3 quarters · filed 2014-02-04 | $115.27K derived: sum of 4 quarters · filed 2014-02-04 | $5.85K 10-Q · filed 2013-02-13 | |||||||||||
| 2012-09-30 | $6.29K derived: 10-K 12 month − 10-Q 9 month · filed 2012-12-28 | -$13.29K derived: sum of 2 quarters · filed 2013-08-07 | $9.38K derived: sum of 3 quarters · filed 2013-08-07 | -$162.85K 10-K · filed 2012-12-28 | -$100.04K 10-K · filed 2012-12-28 | |||||||||||
| 2012-06-30 | -$19.58K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-08-07 | $3.08K derived: sum of 2 quarters · filed 2013-08-07 | -$169.15K 10-Q · filed 2013-08-07 | -$106.33K 10-Q · filed 2012-08-13 | ||||||||||||
| 2012-03-31 | $22.66K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-05-09 | -$149.57K 10-Q · filed 2013-05-09 | -$86.75K 10-Q · filed 2012-05-08 | |||||||||||||
| 2011-12-31 | -$172.23K 10-Q · filed 2013-02-13 | -$109.42K 10-Q · filed 2012-02-09 | ||||||||||||||
| 2011-09-30 | $62.81K 10-Q · filed 2012-08-13 | |||||||||||||||
| 2011-06-30 | $62.81K 10-Q · filed 2011-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |